DK200001151A - New crystalline form of 6-hydroxy-3 - (- [2- (piperidin-1-yl) ethoxy] phenoxy) -2- (4-methoxyphenyl) benzo [b] thiophene hydrochloride - Google Patents

New crystalline form of 6-hydroxy-3 - (- [2- (piperidin-1-yl) ethoxy] phenoxy) -2- (4-methoxyphenyl) benzo [b] thiophene hydrochloride Download PDF

Info

Publication number: DK200001151A
Authority: DK; Denmark
Prior art keywords: piperidin; benzo; phenoxy; ethoxy; hydroxy
Prior art date: 1999-07-29

Application number

DK200001151A

Other languages

Danish (da)

Inventor

Julie Kay Bush

Preston Charles Conrad

Merlyn Gerard Flom

Wayne Douglas Luke

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-29

Filing date

2000-07-28

Publication date

2001-01-30

2000-07-28 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2001-01-30 Publication of DK200001151A publication Critical patent/DK200001151A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

Description

Patentkrav : 1. Krystallinsk 6-hydroxy-3-(4-[2-(piperidin-l-yl)-ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen hy-drochlorid hydrat (F-I), der har et røntgenstrålediffraktionsmønster, som omfatter de følgende toppe: 7,9 +_0,2, 10,7 +0,2, 14,9 +0,2, 15,9 +0,2, 18,3 +0,2 og 20,6 +0,2° i 2Θ, når det er opnået fra en kobberbestrålingskilde. 2. Lægemiddelformulering omfattende den krystallinske forbindelse ifølge krav 1, en eller flere lægemiddelbærere, fortyndingsmidler eller excipiens, og eventuelt østrogen, eventuelt progestin, eventuelt en aromatasein-hibitor, eventuelt en LHRH-analog og eventuelt en acetyl-cholinesterase(AChE)inhibitor. 3. Formulering ifølge krav 2, som omfatter den krystallinske forbindelse ifølge krav 1, en eller flere lægemiddelbærere, fortyndingsmidler eller excipiens, og østrogen . 4. Formulering ifølge krav 3, hvori østrogenet er Prema-rin®. 5. Formulering ifølge krav 2, som omfatter den krystallinske forbindelse ifølge krav 1, en eller flere lægemiddelbærere, fortyndingsmidler eller excipiens og progestin . 6. Formulering ifølge krav 5, hvori progestinet er valgt blandt gruppen bestående af norethylnodrel og norethin-dron. 7. Formulering ifølge krav 2, som omfatter den krystallinske forbindelse ifølge krav 1, en eller flere lægemiddelbærere, fortyndingsmidler eller excipiens og en AChE-inhibitor. 8. Formulering ifølge krav 7, hvori AChE-inhibitoren er valgt blandt gruppen bestående af physostigminsalicylat, tacrin hydrochlorid og donepezil hydrochlorid. 9. Formulering ifølge krav 2, som omfatter den krystallinske forbindelse ifølge krav 1, en eller flere lægemiddelbærere, fortyndingsmidler eller excipiens, østrogen og progestin. 10. Forbindelsen ifølge krav 1 til undertrykkelse af patologiske tilstande valgt blandt gruppen bestående af livmoderfibrosis, endometriosis, aortal glatmuskelcelle-formering, restenosis, brystcancer, livmodercancer, pro-statacancer, godartet prostata-hyperplasia, bentab, osteoporosis, hjerte/karsygdomme, hyperlipidomia, CNS-forstyrrelser og Alzheimers syge. 11. Forbindelsen ifølge krav 10 til undertrykkelse af brystcancer. 12. Forbindelsen ifølge krav 11, hvori undertrykkelsesmåden er profylaktisk. 13. Forbindelsen ifølge krav 10 til undertrykkelse af ovariecancer. 14. Forbindelsen ifølge krav 10 til undertrykkelse af en-dometrial cancer. 15. Forbindelsen ifølge krav 1 til opregulering af cho-lin-acetyltransferase (ChAT) i pattedyr. 16. Fremgangsmåde til fremstilling af forbindelse ifølge krav 1, som omfatter krystallisering af 6-hydroxy-3-(4-[2-(piperidin-l-yl)ethoxyjphenoxy)-2-(4-methoxy-phenyl)-benzo[b]thiophen hydrochlorid fra tetrahydrofuran.Patent claims: 1. Crystalline 6-hydroxy-3- (4- [2- (piperidin-1-yl) -ethoxy] phenoxy) -2- (4-methoxyphenyl) benzo [b] thiophene hydrochloride hydrate (FI), having an X-ray diffraction pattern which includes the following peaks: 7.9 + _0.2, 10.7 +0.2, 14.9 +0.2, 15.9 +0.2, 18.3 +0.2 and 20.6 + 0.2 ° in 2Θ when obtained from a copper radiation source. A drug formulation comprising the crystalline compound of claim 1, one or more drug carriers, diluents or excipients, and optionally estrogen, optionally progestin, optionally an aromatasein inhibitor, optionally an LHRH analog, and optionally an acetylcholinesterase (AChE) inhibitor. The formulation of claim 2 comprising the crystalline compound of claim 1, one or more drug carriers, diluents or excipients, and estrogen. The formulation of claim 3, wherein the estrogen is Premarin®. The formulation of claim 2, comprising the crystalline compound of claim 1, one or more drug carriers, diluents or excipients, and progestin. The formulation of claim 5, wherein the progestin is selected from the group consisting of norethylnodrel and norethrin drone. A formulation according to claim 2, comprising the crystalline compound of claim 1, one or more drug carriers, diluents or excipients and an AChE inhibitor. The formulation of claim 7, wherein the AChE inhibitor is selected from the group consisting of physostigmine salicylate, tacrine hydrochloride and donepezil hydrochloride. A formulation according to claim 2, comprising the crystalline compound of claim 1, one or more drug carriers, diluents or excipients, estrogen and progestin. The compound of claim 1 for the suppression of pathological conditions selected from the group consisting of uterine fibrosis, endometriosis, aortic smooth muscle cell proliferation, restenosis, breast cancer, uterine cancer, prostate cancer, benign prostate hyperplasia, bone loss, osteoporosis, cardiovascular disease, CNS disorders and Alzheimer's disease. The compound of claim 10 for suppressing breast cancer. The compound of claim 11, wherein the mode of suppression is prophylactic. The compound of claim 10 for suppressing ovarian cancer. The compound of claim 10 for suppressing endometrial cancer. The compound of claim 1 for up-regulating choline acetyltransferase (ChAT) in mammals. A process for preparing the compound of claim 1 which comprises crystallizing 6-hydroxy-3- (4- [2- (piperidin-1-yl) ethoxy] phenoxy) -2- (4-methoxy-phenyl) -benzo [b ] thiophene hydrochloride from tetrahydrofuran.

DK200001151A 1999-07-29 2000-07-28 New crystalline form of 6-hydroxy-3 - (- [2- (piperidin-1-yl) ethoxy] phenoxy) -2- (4-methoxyphenyl) benzo [b] thiophene hydrochloride DK200001151A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US14628699P	1999-07-29	1999-07-29
US14757099P	1999-08-06	1999-08-06
US14977399P	1999-08-19	1999-08-19

Publications (1)

Publication Number	Publication Date
DK200001151A true DK200001151A (en)	2001-01-30

Family

ID=27386379

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK200001151A DK200001151A (en)	1999-07-29	2000-07-28	New crystalline form of 6-hydroxy-3 - (- [2- (piperidin-1-yl) ethoxy] phenoxy) -2- (4-methoxyphenyl) benzo [b] thiophene hydrochloride

Country Status (44)

Country	Link
EP (1)	EP1204656A2 (en)
JP (1)	JP2001064277A (en)
KR (1)	KR100697177B1 (en)
CN (1)	CN1138770C (en)
AR (1)	AR031073A1 (en)
AT (1)	AT502318A1 (en)
AU (1)	AU6335600A (en)
BE (1)	BE1013411A3 (en)
BR (1)	BR0003209A (en)
CA (1)	CA2314682A1 (en)
CO (1)	CO5180570A1 (en)
CZ (1)	CZ299311B6 (en)
DE (1)	DE10036854A1 (en)
DK (1)	DK200001151A (en)
DZ (1)	DZ3060A1 (en)
FI (1)	FI20001722A7 (en)
FR (1)	FR2796944B1 (en)
GB (1)	GB2352717A (en)
GR (1)	GR1004084B (en)
HR (1)	HRP20000503B1 (en)
HU (1)	HUP0003001A2 (en)
ID (1)	ID27078A (en)
IL (1)	IL137553A (en)
IT (1)	IT1318660B1 (en)
LT (1)	LT4790B (en)
LU (1)	LU90617B1 (en)
LV (1)	LV12623B (en)
MD (1)	MD2336G2 (en)
MX (1)	MXPA00007461A (en)
MY (1)	MY128764A (en)
NL (1)	NL1015821C2 (en)
NO (1)	NO20003879L (en)
PE (1)	PE20010385A1 (en)
PL (1)	PL341749A1 (en)
PT (1)	PT102502A (en)
RO (1)	RO121851B1 (en)
SE (1)	SE0002792L (en)
SG (1)	SG91296A1 (en)
SI (1)	SI20426A (en)
SV (1)	SV2002000132A (en)
TR (1)	TR200002206A2 (en)
TW (1)	TWI276437B (en)
UA (1)	UA72885C2 (en)
WO (1)	WO2001009116A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU6335500A (en) *	1999-07-29	2001-02-19	Eli Lilly And Company	A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride
CA2408563A1 (en) *	2000-05-08	2001-11-15	Eli Lilly And Company	Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
EP1757291A3 (en) *	2000-05-08	2009-07-15	Eli Lilly & Company	Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
US7122203B2 (en)	2000-05-08	2006-10-17	Eli Lilly And Company	Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
EP1157996A1 (en) *	2000-05-23	2001-11-28	JENAPHARM GmbH	New solid forms of mesoprogestin 11beta-(4E-(hydroxyiminomethyl)-phenyl)-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on
CA2426007A1 (en) *	2000-10-20	2002-05-02	Eli Lilly And Company	A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
AU2002230409A1 (en)	2000-11-27	2002-06-03	Eli Lilly And Company	Process for preparing 3-aryl-benzo(b)thiophenes
CA2393720C (en) *	2002-07-12	2010-09-14	Eli Lilly And Company	Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
PT1773811E (en) *	2004-07-22	2010-10-19	Lilly Co Eli	A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5510357A (en)	1995-02-28	1996-04-23	Eli Lilly And Company	Benzothiophene compounds as anti-estrogenic agents
JP3989569B2 (en) *	1995-02-28	2007-10-10	イーライリリーアンドカンパニー	Benzothiophene compounds, intermediates, compositions and methods
ZA9710262B (en) *	1996-11-19	1999-05-13	Lilly Co Eli	Process for the synthesis of benzothiophenes
ZA982877B (en) *	1997-04-09	1999-10-04	Lilly Co Eli	Treatment of central nervous system disorders with selective estrogen receptor modulators.

2000
- 2000-07-17 WO PCT/US2000/016333 patent/WO2001009116A2/en not_active Ceased
- 2000-07-17 EP EP00950223A patent/EP1204656A2/en not_active Ceased
- 2000-07-17 AU AU63356/00A patent/AU6335600A/en not_active Abandoned
- 2000-07-18 LV LVP-00-94A patent/LV12623B/en unknown
- 2000-07-21 RO ROA200000736A patent/RO121851B1/en unknown
- 2000-07-24 CZ CZ20002716A patent/CZ299311B6/en not_active IP Right Cessation
- 2000-07-24 ID IDP20000629D patent/ID27078A/en unknown
- 2000-07-25 HR HR20000503A patent/HRP20000503B1/en not_active IP Right Cessation
- 2000-07-27 NL NL1015821A patent/NL1015821C2/en not_active IP Right Cessation
- 2000-07-27 IL IL13755300A patent/IL137553A/en not_active IP Right Cessation
- 2000-07-27 CO CO00056521A patent/CO5180570A1/en active IP Right Grant
- 2000-07-27 TR TR2000/02206A patent/TR200002206A2/en unknown
- 2000-07-28 KR KR1020000043651A patent/KR100697177B1/en not_active Expired - Fee Related
- 2000-07-28 SI SI200000172A patent/SI20426A/en not_active IP Right Cessation
- 2000-07-28 FI FI20001722A patent/FI20001722A7/en unknown
- 2000-07-28 MY MYPI20003453A patent/MY128764A/en unknown
- 2000-07-28 LT LT2000076A patent/LT4790B/en not_active IP Right Cessation
- 2000-07-28 NO NO20003879A patent/NO20003879L/en not_active Application Discontinuation
- 2000-07-28 AR ARP000103928A patent/AR031073A1/en unknown
- 2000-07-28 BR BR0003209-3A patent/BR0003209A/en not_active Application Discontinuation
- 2000-07-28 AT AT0132400A patent/AT502318A1/en not_active Application Discontinuation
- 2000-07-28 TW TW089115154A patent/TWI276437B/en not_active IP Right Cessation
- 2000-07-28 GB GB0018641A patent/GB2352717A/en not_active Withdrawn
- 2000-07-28 SG SG200004288A patent/SG91296A1/en unknown
- 2000-07-28 IT IT2000MI001759A patent/IT1318660B1/en active
- 2000-07-28 MX MXPA00007461A patent/MXPA00007461A/en active IP Right Grant
- 2000-07-28 UA UA2000074563A patent/UA72885C2/en unknown
- 2000-07-28 BE BE2000/0478A patent/BE1013411A3/en not_active IP Right Cessation
- 2000-07-28 FR FR0009969A patent/FR2796944B1/en not_active Expired - Fee Related
- 2000-07-28 SV SV2000000132A patent/SV2002000132A/en unknown
- 2000-07-28 GR GR20000100265A patent/GR1004084B/en unknown
- 2000-07-28 PT PT102502A patent/PT102502A/en not_active IP Right Cessation
- 2000-07-28 PL PL00341749A patent/PL341749A1/en not_active Application Discontinuation
- 2000-07-28 HU HU0003001A patent/HUP0003001A2/en unknown
- 2000-07-28 JP JP2000228939A patent/JP2001064277A/en active Pending
- 2000-07-28 SE SE0002792A patent/SE0002792L/en unknown
- 2000-07-28 MD MDA20000162A patent/MD2336G2/en not_active IP Right Cessation
- 2000-07-28 CN CNB001222376A patent/CN1138770C/en not_active Expired - Fee Related
- 2000-07-28 LU LU90617A patent/LU90617B1/en active
- 2000-07-28 DK DK200001151A patent/DK200001151A/en not_active Application Discontinuation
- 2000-07-28 CA CA002314682A patent/CA2314682A1/en not_active Abandoned
- 2000-07-28 DE DE10036854A patent/DE10036854A1/en not_active Withdrawn
- 2000-07-29 DZ DZ000126A patent/DZ3060A1/en active
- 2000-07-31 PE PE2000000757A patent/PE20010385A1/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0003001A2 (en)	2002-04-29
MD2336F2 (en)	2003-12-31
CA2314682A1 (en)	2001-01-29
ID27078A (en)	2001-02-22
SG91296A1 (en)	2002-09-17
FR2796944B1 (en)	2003-01-31
GR20000100265A (en)	2001-03-30
UA72885C2 (en)	2005-05-16
DE10036854A1 (en)	2001-03-01
PE20010385A1 (en)	2001-04-06
HK1035370A1 (en)	2001-11-23
NO20003879L (en)	2001-01-30
FI20001722A0 (en)	2000-07-28
NL1015821C2 (en)	2002-01-03
SV2002000132A (en)	2002-06-07
SE0002792L (en)	2001-01-30
IL137553A0 (en)	2001-07-24
AU6335600A (en)	2001-02-19
KR20010049916A (en)	2001-06-15
GR1004084B (en)	2002-12-11
AR031073A1 (en)	2003-09-10
MD2336G2 (en)	2004-06-30
JP2001064277A (en)	2001-03-13
LV12623B (en)	2001-07-20
CN1138770C (en)	2004-02-18
NO20003879D0 (en)	2000-07-28
CN1288007A (en)	2001-03-21
RO121851B1 (en)	2008-06-30
MY128764A (en)	2007-02-28
HU0003001D0 (en)	2000-10-28
FI20001722L (en)	2001-01-30
PL341749A1 (en)	2001-02-12
AT502318A1 (en)	2007-02-15
EP1204656A2 (en)	2002-05-15
LT4790B (en)	2001-05-25
LV12623A (en)	2001-03-20
WO2001009116A3 (en)	2001-05-17
CZ299311B6 (en)	2008-06-18
HRP20000503B1 (en)	2008-04-30
ITMI20001759A0 (en)	2000-07-28
IE20000605A1 (en)	2001-04-04
BR0003209A (en)	2001-03-20
BE1013411A3 (en)	2001-12-04
GB2352717A (en)	2001-02-07
CO5180570A1 (en)	2002-07-30
FI20001722A7 (en)	2001-01-30
LU90617B1 (en)	2001-06-15
GB0018641D0 (en)	2000-09-13
SI20426A (en)	2001-06-30
TR200002206A2 (en)	2001-03-21
NL1015821A1 (en)	2001-01-30
IL137553A (en)	2005-09-25
KR100697177B1 (en)	2007-03-21
WO2001009116A2 (en)	2001-02-08
IT1318660B1 (en)	2003-08-27
TWI276437B (en)	2007-03-21
FR2796944A1 (en)	2001-02-02
MXPA00007461A (en)	2004-07-16
LT2000076A (en)	2001-02-26
ITMI20001759A1 (en)	2002-01-28
PT102502A (en)	2001-01-31
MD20000162A (en)	2001-04-30
DZ3060A1 (en)	2004-05-22
HRP20000503A2 (en)	2001-06-30
SE0002792D0 (en)	2000-07-28
CZ20002716A3 (en)	2001-05-16

Publication	Publication Date	Title
DK200001150A (en)	2001-01-30	New crystalline form of 6-hydroxy-3- (4- [2- (piperidin-1-yl) ethoxy] phenoxy) -2- (4-methoxyphenyl) benzo [b] thiophene hydrochloride
DK200001151A (en)	2001-01-30	New crystalline form of 6-hydroxy-3 - (- [2- (piperidin-1-yl) ethoxy] phenoxy) -2- (4-methoxyphenyl) benzo [b] thiophene hydrochloride
EP2135620A1 (en)	2009-12-23	Ocular hypotensive agent comprising compound capable of inhibiting histone deacetylase as active ingredient
EP0838464B1 (en)	2003-09-10	Substituted benzo(b)thiophene compounds having activity as selective estrogen receptor modulators
JP2001523676A (en)	2001-11-27	2-Arylbenzo [b] thiophenes useful for treating estrogen deficiency syndrome
US6403615B1 (en)	2002-06-11	2-Aryl-3-aroylbenzo {b} thiophenes useful for the treatment of estrogen deprivation syndrome
EP0831089B1 (en)	2003-08-13	Benzothiophene compounds, intermediates, processes, compositions, and methods
EP0832888B1 (en)	2003-07-23	Benzothiophene compounds, compositions, and methods
RU2000120574A (en)	2002-06-10	NEW CRYSTALLINE FORM 6-HYDROXY-3- (4- [2- (PIPERIDIN-1-IL) ETOXI] PHENOXY) -2- (4-METHOFYNYL) BENZ [b] TIOPHENE HYDROCHLORIDE
RU2000120575A (en)	2002-06-10	NEW CRYSTALLINE FORM of 6-HYDROXY-3- (4- [2- (PIPERIDIN-1-IL) ETOXY] PHENOXY) -2- (4-METHOXYPHENYL) BENZE [b] THIOPHENE HYDROCHLORIDE
WO1999007693A1 (en)	1999-02-18	Benzothiophenes
US6133458A (en)	2000-10-17	Benzo[B]indeno[2, 1-D]thiophene compounds, intermediates, compositions, and methods
WO2002034741A3 (en)	2003-01-03	A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE
KR20010006215A (en)	2001-01-26	Prevention of Breast Cancer with Selective Estrogen Receptor Modulators
EP0838461A2 (en)	1998-04-29	Substituted 2,3-aryl-benzothiophene compounds having estrogenic activity
EP0835872A1 (en)	1998-04-15	Benzo [b] thiophene compounds, intermediates, formulations, and methods
EP0832891B1 (en)	2003-07-30	Dihydrobenzo (B) indeno (2,1-D) thiophene compounds, intermediates, processes, compositions, and methods
Cotelle et al.	2004	Synthesis, x‐ray structure and spectroscopic and electronic properties of two new synthesized flavones
HK1020679A (en)	2000-05-19	2-aryl-3-aroylbenzo(b)thiophenes useful for the treatment of estrogen deprivation syndrome

Legal Events

Date	Code	Title	Description
2009-11-09	AHS	Application shelved for other reasons than non-payment